NEW YORK--(BUSINESS WIRE)--TriGemX Bio, a biotechnology company focused on developing a first-in-class medicine for the treatment of migraine, today announced the appointment of Doug Pagán to its Board of Directors. "We are thrilled to welcome Doug to our Board of Directors at this pivotal moment," said Jeff Goater, CEO of TriGemX Bio. "As we advance Phase 3 development of elismetrep and prepare for our next stage of growth, Doug's financial expertise and deep industry experience helping biotec
TriGemX Bio Strengthens Board of Directors with Appointment of Doug Pagán
